A simple blood test could recognize that Alzheimer's risk up to 15 years earlier Symptoms of illness appearOpening the Prospect of nationwide screening to whom you should send it Population over 50. A turning point against the most widespread form of dementia.
The exam measures levels of p-tau217 protein, an indicator of the changes that occur in the brain during Alzheimer's disease. The test is already commercially available in the United Kingdom – we read in the British newspaper “Independent” -. The analysis could identify people with a high, medium or low likelihood of developing the disease, potentially eliminating the need for further, more invasive testing.
In one Study on 786 peoplemoderated by Nicholas Ashton's teamUniversity of Gothenburg (Sweden) e published in “Jama Neurology”, Scientists were able to classify the risk of Alzheimer's disease: The higher the p-tau217 protein level in the blood, the more likely or advanced the disease was. Of a Research from University College London It also shows that the test could detect Alzheimer's up to 15 years before symptoms appear.
Currently the only way to detect the accumulation of proteins in the brain associated with the “memory thief”. consists of performing a lumbar puncture or using imaging techniques available in some centers. Swedish studies show the blood test can detect signs of Alzheimer's with the same accuracy as lumbar punctures and better than a number of other tests currently being worked on.
The Importance of Discovery
David Curtis, honorary professor at the Ucl Genetics Institute, suggests a possible revolution for the early diagnosis of pathology“Everyone over 50 could be routinely screened every few years, just as they are now regularly tested for high cholesterol,” he explains.
For Sheona Scales, research director at Alzheimer's Research UK, thanks to the new data we have “a growing body of evidence that this particular test has enormous potential to revolutionize diagnosis in people with suspected Alzheimer's disease.”
Richard Oakley, deputy director of research and innovation atAlzheimer's Society EnglishHe calls it “an extremely positive step in the right direction.” In addition, according to the expert, “the results of these tests could be so clear that for some people with Alzheimer's disease no further follow-up tests are required, which could significantly speed up the diagnostic process in the future. However – he specifies – we are still. “More research is needed on different patient groups to understand how effective these tests are for everyone suffering from the pathology.”